Anti-Arylsulfatase A Antibody, clone 2C19 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Arylsulfatase A (UniProt: P15289; also known as EC:3.1.6.8, ASA, ARSA, Cerebroside-sulfatase) is encoded by the ARSA gene (Gene ID: 410) in human. Arylsulfatases are shown to occur in various tissues and fluids and are classified into A, B and C enzymes. Of these, the B and C enzymes act to desulfate sulfated glycosaminoglycans and steroid sulfates, respectively. Arylsulfatase A that is detected in endoplasmic reticulum (ER) and in lysosomes catalyzes the desulfation of 3-O-sulfogalactosyl residues in glycosphingolipids. The conversion to 3-oxoalanine of a serine or cysteine residue in prokaryotes and of a cysteine residue in eukaryotes, is reported to be critical for catalytic activity. Its enzymatic activity requires the presence of saposin B as an activator. Arylsulfatase A activity is inhibited by phosphate groups that form a covalent bond with the active site 3-oxoalanine. It is synthesized with a signal peptide (aa 1-18), which is subsequently cleaved off to produce the mature form that can exist as a homodimer at neutral pH or as a homooctamer at acidic pH. Mutations in ARSA gene are known to cause metachromatic leukodystrophy (MLD), an autosomal recessive disease caused by abnormal intra-lysosomal accumulation of cerebroside-3-sulfate in central and peripheral nervous systems and other organs. It is characterized by leukodystrophy, progressive demyelination and a variety of neurological symptoms, including gait disturbances, ataxias, optical atrophy, dementia, seizures, and spastic tetraparesis. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Chruszcz, M., et al. (2003). J. Inorg. Biochem. 96(2-3); 386-392; Felice, KJ., et al. (2000). Neurology. 55(7); 1036-1039; Qu, Y., et al. (1999). Mol. Genet. Metab. 67(3); 206-212).

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

KLH-conjugated linear peptide corresponding to 25 amino acids from the N-terminal half of human Arylsulfatase A.

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Arylsulfatase A in HeLa cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Arylsulfatase A in lysates from HL-60, U2OS, cells and Human stomach tissue.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Arylsulfatase A in human stomach tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound Arylsulfatase A peptide with a KD of 1.1 x 10-6 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 2C19 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects Arylsulfatase A. It targets an epitope within 25 amino acids within the N-terminal half.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Reconstitute lyophilized antibody pellet with 25μL of ultrapure water or Phosphate Buffered Saline (PBS). Please refer to our reconstitution protocol and the specific application guidance on the suggested starting dilutions and sample type.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.